Dr. Kaplan on the RELEVANCE Trial in Follicular Lymphoma
In Partnership With:
Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the RELEVANCE trial in previously untreated patients with follicular lymphoma.
Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the RELEVANCE trial in previously untreated patients with follicular lymphoma.
The combination of rituximab (Rituxan) and lenalidomide (Revlimid; R2) failed to meet its co-primary endpoint of progression-free survival versus rituximab and chemotherapy in the phase III RELEVANCE trial.
The superiority design of the trial was very ambitious, explains Kaplan. Though R2 missed its endpoint, Kaplan notes that the outcomes between the chemotherapy/rituximab regimens and the lenalidomide/rituximab regimen were very similar. This lends supports to the idea of using a non-chemotherapy regimen as frontline therapy. The regimen is a great treatment for patients with relapsed/refractory disease, according to Kaplan, who says that it currently serves as his standard second-line treatment. As time goes on, Kaplan predicts that this will become a favored approach for patients, especially those who may not be the best candidates for a chemotherapy-based regimen.
